journal
https://read.qxmd.com/read/33422192/optimising-prehospital-stroke-triage-in-a-changing-landscape
#1
Mayank Goyal, Martha Marko
No abstract text is available yet for this article.
January 7, 2021: Lancet Neurology
https://read.qxmd.com/read/33422191/comparison-of-eight-prehospital-stroke-scales-to-detect-intracranial-large-vessel-occlusion-in-suspected-stroke-presto-a-prospective-observational-study
#2
Martijne H C Duvekot, Esmee Venema, Anouk D Rozeman, Walid Moudrous, Frédérique H Vermeij, Marileen Biekart, Hester F Lingsma, Lisette Maasland, Annemarie D Wijnhoud, Laus J M M Mulder, Kees C L Alblas, Roeland P J van Eijkelenburg, Bianca I Buijck, Jeannette Bakker, Aarnout S Plaisier, Jan-Hein Hensen, Geert J Lycklama À Nijeholt, Pieter Jan van Doormaal, Adriaan C G M van Es, Aad van der Lugt, Henk Kerkhoff, Diederik W J Dippel, Bob Roozenbeek
BACKGROUND: Due to the time-sensitive effect of endovascular treatment, rapid prehospital identification of large-vessel occlusion in individuals with suspected stroke is essential to optimise outcome. Interhospital transfers are an important cause of delay of endovascular treatment. Prehospital stroke scales have been proposed to select patients with large-vessel occlusion for direct transport to an endovascular-capable intervention centre. We aimed to prospectively validate eight prehospital stroke scales in the field...
January 7, 2021: Lancet Neurology
https://read.qxmd.com/read/33357512/safety-and-efficacy-of-riluzole-in-patients-undergoing-decompressive-surgery-for-degenerative-cervical-myelopathy-csm-protect-a-multicentre-double-blind-placebo-controlled-randomised-phase-3-trial
#3
Michael G Fehlings, Jetan H Badhiwala, Henry Ahn, H Francis Farhadi, Christopher I Shaffrey, Ahmad Nassr, Praveen Mummaneni, Paul M Arnold, W Bradley Jacobs, K Daniel Riew, Michael Kelly, Darrel S Brodke, Alexander R Vaccaro, Alan S Hilibrand, Jason Wilson, James S Harrop, S Tim Yoon, Kee D Kim, Daryl R Fourney, Carlo Santaguida, Eric M Massicotte, Branko Kopjar
BACKGROUND: Degenerative cervical myelopathy represents the most common form of non-traumatic spinal cord injury. This trial investigated whether riluzole enhances outcomes in patients undergoing decompression surgery for degenerative cervical myelopathy. METHODS: This multicentre, double-blind, placebo-controlled, randomised, phase 3 trial was done at 16 university-affiliated centres in Canada and the USA. Patients with moderate-to-severe degenerative cervical myelopathy aged 18-80 years, who had a modified Japanese Orthopaedic Association (mJOA) score of 8-14, were eligible...
December 22, 2020: Lancet Neurology
https://read.qxmd.com/read/33357511/a-new-dimension-in-degenerative-cervical-myelopathy
#4
Ronald H M A Bartels
No abstract text is available yet for this article.
December 22, 2020: Lancet Neurology
https://read.qxmd.com/read/33357515/surgical-decompression-in-acute-spinal-cord-injury-earlier-is-better
#5
Andrew I R Maas, Wilco Peul, Claudius Thomé
No abstract text is available yet for this article.
December 21, 2020: Lancet Neurology
https://read.qxmd.com/read/33357514/the-influence-of-timing-of-surgical-decompression-for-acute-spinal-cord-injury-a-pooled-analysis-of-individual-patient-data
#6
Jetan H Badhiwala, Jefferson R Wilson, Christopher D Witiw, James S Harrop, Alexander R Vaccaro, Bizhan Aarabi, Robert G Grossman, Fred H Geisler, Michael G Fehlings
BACKGROUND: Although there is a strong biological rationale for early decompression of the injured spinal cord, the influence of the timing of surgical decompression for acute spinal cord injury (SCI) remains debated, with substantial variability in clinical practice. We aimed to objectively evaluate the effect of timing of decompressive surgery for acute SCI on long-term neurological outcomes. METHODS: We did a pooled analysis of individual patient data derived from four independent, prospective, multicentre data sources, including data from December, 1991, to March, 2017...
December 21, 2020: Lancet Neurology
https://read.qxmd.com/read/33347807/healthy-eating-for-secondary-stroke-prevention
#7
Simiao Wu, Craig S Anderson
No abstract text is available yet for this article.
December 18, 2020: Lancet Neurology
https://read.qxmd.com/read/33347806/the-role-of-diet-in-secondary-stroke-prevention
#8
REVIEW
Coralie English, Lesley MacDonald-Wicks, Amanda Patterson, John Attia, Graeme J Hankey
Poor quality diet and nutrition is strongly associated with risk of first stroke, and adherence to a Mediterranean-style diet has been reported to reduce the risk of first stroke. The association between diet quality and the risk of recurrent stroke is less certain and there is no reliable evidence that improving diet quality or dietary supplementation reduces recurrent stroke risk. Current evidence is largely based on epidemiological studies of diverse dietary approaches, ranging from nutritional supplements to specific foods, food groups, and dietary patterns, and is difficult to interpret...
December 18, 2020: Lancet Neurology
https://read.qxmd.com/read/33341150/genetic-determinants-of-survival-in-progressive-supranuclear-palsy-a-genome-wide-association-study
#9
Edwin Jabbari, Shunsuke Koga, Rebecca R Valentino, Regina H Reynolds, Raffaele Ferrari, Manuela M X Tan, James B Rowe, Clifton L Dalgard, Sonja W Scholz, Dennis W Dickson, Thomas T Warner, Tamas Revesz, Günter U Höglinger, Owen A Ross, Mina Ryten, John Hardy, Maryam Shoai, Huw R Morris
BACKGROUND: The genetic basis of variation in the progression of primary tauopathies has not been determined. We aimed to identify genetic determinants of survival in progressive supranuclear palsy (PSP). METHODS: In stage one of this two stage genome-wide association study (GWAS), we included individuals with PSP, diagnosed according to pathological and clinical criteria, from two separate cohorts: the 2011 PSP GWAS cohort, from brain banks based at the Mayo Clinic (Jacksonville, FL, USA) and in Munich (Germany), and the University College London PSP cohort, from brain banks and the PROSPECT study, a UK-wide longitudinal study of patients with atypical parkinsonian syndromes...
December 17, 2020: Lancet Neurology
https://read.qxmd.com/read/33341149/forecasting-seizure-risk-in-adults-with-focal-epilepsy-a-development-and-validation-study
#10
Timothée Proix, Wilson Truccolo, Marc G Leguia, Thomas K Tcheng, David King-Stephens, Vikram R Rao, Maxime O Baud
BACKGROUND: People with epilepsy are burdened with the apparent unpredictability of seizures. In the past decade, converging evidence from studies using chronic EEG (cEEG) revealed that epileptic brain activity shows robust cycles, operating over hours (circadian) and days (multidien). We hypothesised that these cycles can be leveraged to estimate future seizure probability, and we tested the feasibility of forecasting seizures days in advance. METHODS: We did a feasibility study in distinct development and validation cohorts, involving retrospective analysis of cEEG data recorded with an implanted device in adults (age ≥18 years) with drug-resistant focal epilepsy followed at 35 centres across the USA between Jan 19, 2004, and May 18, 2018...
December 17, 2020: Lancet Neurology
https://read.qxmd.com/read/33341148/lrrk2-and-survival-in-progressive-supranuclear-palsy
#11
Alice S Chen-Plotkin
No abstract text is available yet for this article.
December 17, 2020: Lancet Neurology
https://read.qxmd.com/read/33341147/advancing-seizure-forecasting-from-cyclical-activity-data
#12
Mark J Cook
No abstract text is available yet for this article.
December 17, 2020: Lancet Neurology
https://read.qxmd.com/read/33253627/sars-cov-2-and-the-risk-of-parkinson-s-disease-facts-and-fantasy
#13
Marcelo Merello, Kailash P Bhatia, Jose A Obeso
No abstract text is available yet for this article.
November 27, 2020: Lancet Neurology
https://read.qxmd.com/read/33245858/safety-and-efficacy-of-prednisone-versus-placebo-in-short-term-prevention-of-episodic-cluster-headache-a-multicentre-double-blind-randomised-controlled-trial
#14
Mark Obermann, Steffen Nägel, Claudia Ose, Nilüfer Sonuc, André Scherag, Peter Storch, Charly Gaul, Andreas Böger, Torsten Kraya, Jan-Peter Jansen, Andreas Straube, Tobias Freilinger, Holger Kaube, Tim P Jürgens, Hans-Christoph Diener, Zaza Katsarava, Christoph Kleinschnitz, Dagny Holle
BACKGROUND: Prednisone is commonly used for initial short-term therapy of episodic cluster headaches before preventive medication such as verapamil becomes effective, but this strategy has not been tested in large randomised trials. We aimed to access the safety and efficacy of this treatment approach. METHODS: This study was a multicentre, randomised, double-blind, placebo-controlled trial done in ten specialised headache centres in Germany. Patients with episodic cluster headaches who were aged between 18 and 65 years and within a current pain episode for not more than 30 days, received 100 mg oral prednisone for 5 days followed by tapering of 20 mg every 3 days, or matching placebo (17 days total exposure)...
November 24, 2020: Lancet Neurology
https://read.qxmd.com/read/33242420/are-drugs-for-multiple-sclerosis-fatigue-just-placebos
#15
Dennis Bourdette
No abstract text is available yet for this article.
November 23, 2020: Lancet Neurology
https://read.qxmd.com/read/33242419/safety-and-efficacy-of-amantadine-modafinil-and-methylphenidate-for-fatigue-in-multiple-sclerosis-a-randomised-placebo-controlled-crossover-double-blind-trial
#16
Bardia Nourbakhsh, Nisha Revirajan, Bridget Morris, Christian Cordano, Jennifer Creasman, Michael Manguinao, Kristen Krysko, Alice Rutatangwa, Caroline Auvray, Salman Aljarallah, Chengshi Jin, Ellen Mowry, Charles McCulloch, Emmanuelle Waubant
BACKGROUND: Methylphenidate, modafinil, and amantadine are commonly prescribed medications for alleviating fatigue in multiple sclerosis; however, the evidence supporting their efficacy is sparse and conflicting. Our goal was to compare the efficacy of these three medications with each other and placebo in patients with multiple sclerosis fatigue. METHODS: In this randomised, placebo-controlled, four-sequence, four-period, crossover, double-blind trial, patients with multiple sclerosis who reported fatigue and had a Modified Fatigue Impact Scale (MFIS) score of more than 33 were recruited at two academic multiple sclerosis centres in the USA...
November 23, 2020: Lancet Neurology
https://read.qxmd.com/read/33217365/correction-to-lancet-neurol-2020-19-998-1009
#17
(no author information available yet)
No abstract text is available yet for this article.
November 17, 2020: Lancet Neurology
https://read.qxmd.com/read/33212064/patisiran-in-hereditary-transthyretin-mediated-amyloidosis
#18
Marco Luigetti, Serenella Servidei
No abstract text is available yet for this article.
November 16, 2020: Lancet Neurology
https://read.qxmd.com/read/33212063/long-term-safety-and-efficacy-of-patisiran-for-hereditary-transthyretin-mediated-amyloidosis-with-polyneuropathy-12-month-results-of-an-open-label-extension-study
#19
David Adams, Michael Polydefkis, Alejandra González-Duarte, Jonas Wixner, Arnt V Kristen, Hartmut H Schmidt, John L Berk, Inés Asunción Losada López, Angela Dispenzieri, Dianna Quan, Isabel M Conceição, Michel S Slama, Julian D Gillmore, Theodoros Kyriakides, Senda Ajroud-Driss, Márcia Waddington-Cruz, Michelle M Mezei, Violaine Planté-Bordeneuve, Shahram Attarian, Elizabeth Mauricio, Thomas H Brannagan, Mitsuharu Ueda, Emre Aldinc, Jing Jing Wang, Matthew T White, John Vest, Erhan Berber, Marianne T Sweetser, Teresa Coelho
BACKGROUND: Hereditary transthyretin-mediated amyloidosis is a rare, inherited, progressive disease caused by mutations in the transthyretin (TTR) gene. We assessed the safety and efficacy of long-term treatment with patisiran, an RNA interference therapeutic that inhibits TTR production, in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. METHODS: This multicentre, open-label extension (OLE) trial enrolled patients at 43 hospitals or clinical centres in 19 countries as of Sept 24, 2018...
November 16, 2020: Lancet Neurology
https://read.qxmd.com/read/33186537/new-therapies-for-neuromyelitis-optica-spectrum-disorder
#20
REVIEW
Michael Levy, Kazuo Fujihara, Jacqueline Palace
BACKGROUND: Neuromyelitis optica spectrum disorder is an autoimmune disease of the CNS that primarily affects the optic nerves and spinal cord. Most patients have serum antibodies targeting the aquaporin-4 water channel expressed on the end-feet of astrocytes. Although the prevalence of neuromyelitis optica spectrum disorder is limited to around 1-2 people per 100 000, severe immune-mediated attacks can quickly lead to blindness and paralysis if undiagnosed and untreated. However, diagnosis is straightforward when the highly specific serum aquaporin-4 antibodies are detected with cell-based assays...
November 10, 2020: Lancet Neurology
journal
journal
20188
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"